Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Prognostic Value of Combined Detection of Serum IL6, YKL-40, and C-reactive Protein in Patients with Unresectable Pancreatic Cancer.

Chen IM, Johansen AZ, Dehlendorff C, Jensen BV, Bojesen SE, Pfeiffer P, Bjerregaard JK, Nielsen SE, Andersen F, Holländer NH, Yilmaz MK, Rasmussen LS, Johansen JS.

Cancer Epidemiol Biomarkers Prev. 2019 Nov 4. doi: 10.1158/1055-9965.EPI-19-0672. [Epub ahead of print]

PMID:
31685562
2.

Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer.

Chen IM, Willumsen N, Dehlendorff C, Johansen AZ, Jensen BV, Hansen CP, Hasselby JP, Bojesen SE, Pfeiffer P, Nielsen SE, Holländer NH, Yilmaz MK, Karsdal M, Johansen JS.

Int J Cancer. 2019 Oct 23. doi: 10.1002/ijc.32751. [Epub ahead of print]

PMID:
31642523
3.

A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.

Andersen SE, Andersen IB, Jensen BV, Pfeiffer P, Ota T, Larsen JS.

Acta Oncol. 2019 Aug;58(8):1149-1157. doi: 10.1080/0284186X.2019.1605192. Epub 2019 Apr 19.

PMID:
31002008
4.

Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.

Larsen FO, Jensen BV, Nørgaard HH, Hermann HK, Larsen PN, Markussen A, Hogdall E, Nielsen D.

Oncology. 2019;96(6):299-308. doi: 10.1159/000499314. Epub 2019 Apr 18.

PMID:
30999314
5.

An open label phase 1 study evaluation safety, tolerability, and maximum tolerated dose of oral administration of irinotecan in combination with capecitabine.

Kümler I, Eefsen RL, Sørensen PG, Theile S, Fullerton A, Nielsen PG, Jensen BV, Nielsen DL.

Cancer Chemother Pharmacol. 2019 Aug;84(2):441-446. doi: 10.1007/s00280-019-03819-0. Epub 2019 Apr 4.

PMID:
30949758
6.

Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma.

Obazee O, Archibugi L, Andriulli A, Soucek P, Małecka-Panas E, Ivanauskas A, Johnson T, Gazouli M, Pausch T, Lawlor RT, Cavestro GM, Milanetto AC, Di Leo M, Pasquali C, Hegyi P, Szentesi A, Radu CE, Gheorghe C, Theodoropoulos GE, Bergmann F, Brenner H, Vodickova L, Katzke V, Campa D, Strobel O, Kaiser J, Pezzilli R, Federici F, Mohelnikova-Duchonova B, Boggi U, Lemstrova R, Johansen JS, Bojesen SE, Chen I, Jensen BV, Capurso G, Pazienza V, Dervenis C, Sperti C, Mambrini A, Hackert T, Kaaks R, Basso D, Talar-Wojnarowska R, Maiello E, Izbicki JR, Cuk K, Saum KU, Cantore M, Kupcinskas J, Palmieri O, Delle Fave G, Landi S, Salvia R, Fogar P, Vashist YK, Scarpa A, Vodicka P, Tjaden C, Iskierka-Jazdzewska E, Canzian F.

Int J Cancer. 2019 Aug 1;145(3):686-693. doi: 10.1002/ijc.32127. Epub 2019 Feb 7.

PMID:
30672594
7.

Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer.

Lindgaard SC, Brinch CM, Jensen BK, Nørgaard HH, Hermann KL, Theile S, Larsen FO, Jensen BV, Michelsen H, Nelausen KM, Holm VH, Ekblad L, Soerensen PG, Nielsen DL.

Breast. 2019 Feb;43:113-119. doi: 10.1016/j.breast.2018.12.002. Epub 2018 Dec 5.

PMID:
30544058
8.

Oral administration of irinotecan in patients with solid tumors: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics.

Kümler I, Sørensen PG, Palshof J, Høgdall E, Skovrider-Ruminski W, Theile S, Fullerton A, Nielsen PG, Jensen BV, Nielsen DL.

Cancer Chemother Pharmacol. 2019 Jan;83(1):169-178. doi: 10.1007/s00280-018-3720-7. Epub 2018 Nov 8.

9.

Methodological development and biological observations of cell free DNA with a simple direct fluorescent assay in colorectal cancer.

Boysen AK, Sørensen BS, Lefevre AC, Abrantes R, Johansen JS, Jensen BV, Schou JV, Larsen FO, Nielsen D, Taflin H, Gustavson B, Wettergren Y, Sorensen BS, Ree AH, Dueland S, Pallisgaard N, Spindler KL.

Clin Chim Acta. 2018 Dec;487:107-111. doi: 10.1016/j.cca.2018.09.029. Epub 2018 Sep 18.

PMID:
30240586
10.

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH.

Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26.

11.

Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer.

Christensen TD, Palshof JA, Larsen FO, Poulsen TS, Høgdall E, Pfeiffer P, Jensen BV, Yilmaz MK, Nielsen D.

Acta Oncol. 2018 Aug;57(8):1057-1062. doi: 10.1080/0284186X.2018.1433322. Epub 2018 Jan 30.

PMID:
29380640
12.

Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.

Schou JV, Larsen FO, Sørensen BS, Abrantes R, Boysen AK, Johansen JS, Jensen BV, Nielsen DL, Spindler KL.

Ann Oncol. 2018 Mar 1;29(3):610-615. doi: 10.1093/annonc/mdx778.

PMID:
29253083
13.

Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.

Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS.

Oncotarget. 2017 Oct 26;8(58):97769-97786. doi: 10.18632/oncotarget.22080. eCollection 2017 Nov 17.

14.

Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.

Spindler KG, Boysen AK, Pallisgård N, Johansen JS, Tabernero J, Sørensen MM, Jensen BV, Hansen TF, Sefrioui D, Andersen RF, Brandslund I, Jakobsen A.

Oncologist. 2017 Sep;22(9):1049-1055. doi: 10.1634/theoncologist.2016-0178. Epub 2017 Aug 4. Review.

15.

Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.

Larsen FO, Markussen A, Nielsen D, Colville-Ebeling B, Riis LB, Jensen BV.

Oncology. 2017;93(3):191-196. doi: 10.1159/000475818. Epub 2017 May 23.

PMID:
28531891
16.

[Patients with colorectal cancer live longer].

Pfeiffer P, Jensen BV.

Ugeskr Laeger. 2017 May 1;179(18). pii: V69138. Danish. No abstract available.

PMID:
28473021
17.

Risk factors for brain metastases in patients with metastatic colorectal cancer.

Christensen TD, Palshof JA, Larsen FO, Høgdall E, Poulsen TS, Pfeiffer P, Jensen BV, Yilmaz MK, Christensen IJ, Nielsen D.

Acta Oncol. 2017 May;56(5):639-645. doi: 10.1080/0284186X.2017.1290272. Epub 2017 Feb 22.

PMID:
28447565
18.

Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.

Palshof JA, Høgdall EV, Poulsen TS, Linnemann D, Jensen BV, Pfeiffer P, Tarpgaard LS, Brünner N, Stenvang J, Yilmaz M, Nielsen DL.

BMC Cancer. 2017 Jan 11;17(1):48. doi: 10.1186/s12885-016-3001-y.

19.

Capecitabine and Oxaliplatin Before, During, and After Radiotherapy for High-Risk Rectal Cancer.

Larsen FO, Markussen A, Jensen BV, Fromm AL, Vistisen KK, Parner VK, Linnemann D, Hansen RH, Johannesen HH, Schou JV.

Clin Colorectal Cancer. 2017 Jun;16(2):e7-e14. doi: 10.1016/j.clcc.2016.07.020. Epub 2016 Sep 14.

PMID:
27743742
20.

Early 18F-FDG-PET/CT as a predictive marker for treatment response and survival in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.

Skougaard K, Nielsen D, Jensen BV, Pfeiffer P, Hendel HW.

Acta Oncol. 2016 Sep - Oct;55(9-10):1175-1182. doi: 10.3109/0284186X.2016.1170197. Epub 2016 Aug 22.

PMID:
27548393
21.

The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer.

Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, Jensen BV, Pfeiffer P, Bojesen SE, Giese N, Nielsen KR, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK.

Int J Cancer. 2016 Nov 15;139(10):2312-24. doi: 10.1002/ijc.30291. Epub 2016 Aug 16.

22.

MicroRNA Expression in Formalin-fixed Paraffin-embedded Cancer Tissue: Identifying Reference MicroRNAs and Variability.

Boisen MK, Dehlendorff C, Linnemann D, Schultz NA, Jensen BV, Høgdall EV, Johansen JS.

BMC Cancer. 2015 Dec 29;15:1024. doi: 10.1186/s12885-015-2030-2.

23.

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.

Spindler KL, Pallisgaard N, Appelt AL, Andersen RF, Schou JV, Nielsen D, Pfeiffer P, Yilmaz M, Johansen JS, Hoegdall EV, Jakobsen A, Jensen BV.

Eur J Cancer. 2015 Nov;51(17):2678-85. doi: 10.1016/j.ejca.2015.06.118. Epub 2015 Oct 24.

PMID:
26508156
24.

Seeding after ultrasound-guided percutaneous biopsy of liver metastases in patients with colorectal or breast cancer.

Chen I, Lorentzen T, Linnemann D, Nolsøe CP, Skjoldbye B, Jensen BV, Nielsen D.

Acta Oncol. 2016 May;55(5):638-43. doi: 10.3109/0284186X.2015.1093657. Epub 2015 Oct 12.

PMID:
26457338
25.

Improved survival with early adjuvant chemotherapy after colonic resection for stage III colonic cancer: A nationwide study.

Klein M, Azaquoun N, Jensen BV, Gögenur I.

J Surg Oncol. 2015 Oct;112(5):538-43. doi: 10.1002/jso.24017. Epub 2015 Aug 14.

PMID:
26271357
26.

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS.

PLoS One. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014.

27.

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.

Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.

PMID:
25011934
28.

CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.

Skougaard K, Johannesen HH, Nielsen D, Schou JV, Jensen BV, Høgdall EV, Hendel HW.

Cancer Med. 2014 Oct;3(5):1294-301. doi: 10.1002/cam4.271. Epub 2014 Jun 18.

29.

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

Schou JV, Rossi S, Jensen BV, Nielsen DL, Pfeiffer P, Høgdall E, Yilmaz M, Tejpar S, Delorenzi M, Kruhøffer M, Johansen JS.

PLoS One. 2014 Jun 18;9(6):e99886. doi: 10.1371/journal.pone.0099886. eCollection 2014.

30.

A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/- targeted therapy.

Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P.

Cancer Treat Rev. 2014 Jul;40(6):701-15. doi: 10.1016/j.ctrv.2014.02.006. Epub 2014 Feb 28. Review.

PMID:
24731471
31.

MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS.

JAMA. 2014 Jan 22-29;311(4):392-404. doi: 10.1001/jama.2013.284664.

PMID:
24449318
32.

Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.

Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV.

Ann Oncol. 2013 Oct;24(10):2554-9. doi: 10.1093/annonc/mdt253. Epub 2013 Jul 17.

PMID:
23864097
33.

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz MK, Holländer NH, Wøjdemann M, Bojesen SE, Nielsen KR, Johansen JS.

PLoS One. 2013 Jun 26;8(6):e67059. doi: 10.1371/journal.pone.0067059. Print 2013.

34.

Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.

Skougaard K, Nielsen D, Jensen BV, Hendel HW.

J Nucl Med. 2013 Jul;54(7):1026-31. doi: 10.2967/jnumed.112.111757. Epub 2013 Apr 9.

35.

High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.

Rasmussen MH, Jensen NF, Tarpgaard LS, Qvortrup C, Rømer MU, Stenvang J, Hansen TP, Christensen LL, Lindebjerg J, Hansen F, Jensen BV, Hansen TF, Pfeiffer P, Brünner N, Ørntoft TF, Andersen CL.

Mol Oncol. 2013 Jun;7(3):637-46. doi: 10.1016/j.molonc.2013.02.016. Epub 2013 Feb 28.

36.

Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.

Appel JM, Zerahn B, Møller S, Christensen HM, Søgaard P, Ejlertsen B, Fogh-Andersen N, Jensen BV, Nielsen DL.

Acta Oncol. 2012 Nov;51(8):1054-61. doi: 10.3109/0284186X.2012.702920. Epub 2012 Aug 22.

PMID:
22909389
37.

Intrahepatic and systemic therapy with oxaliplatin combined with capecitabine in patients with hepatic metastases from breast cancer.

Nielsen DL, Nørgaard H, Vestermark LW, Pfeiffer P, Jensen BK, Nelausen KM, Bergenfeldt M, Hermann KL, Jensen BV.

Breast. 2012 Aug;21(4):556-61. doi: 10.1016/j.breast.2012.05.003. Epub 2012 Jun 4.

38.

Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer.

Schou JV, Larsen FO, Rasch L, Linnemann D, Langhoff J, Høgdall E, Nielsen DL, Vistisen K, Fromm A, Jensen BV.

Ann Oncol. 2012 Oct;23(10):2627-33. Epub 2012 Apr 2.

PMID:
22473488
39.

Observer variability in a phase II trial - assessing consistency in RECIST application.

Skougaard K, McCullagh MJ, Nielsen D, Hendel HW, Jensen BV, Johannesen HH.

Acta Oncol. 2012 Jul;51(6):774-80. doi: 10.3109/0284186X.2012.667149. Epub 2012 Mar 21.

PMID:
22432439
40.

Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer.

Bertini I, Cacciatore S, Jensen BV, Schou JV, Johansen JS, Kruhøffer M, Luchinat C, Nielsen DL, Turano P.

Cancer Res. 2012 Jan 1;72(1):356-64. doi: 10.1158/0008-5472.CAN-11-1543. Epub 2011 Nov 11.

41.

Capecitabine and bevacizumab in heavily pre-treated patients with advanced colorectal cancer.

Larsen FO, Boisen MK, Fromm AL, Jensen BV.

Acta Oncol. 2012 Feb;51(2):231-3. doi: 10.3109/0284186X.2011.614637. Epub 2011 Sep 22.

PMID:
21936753
42.

Comment on 'Treatment of colorectal cancer with and without bevacizumab: a phase III study'.

Boisen MK, Johansen JS, Larsen O, Jensen BV.

Oncology. 2011;80(1-2):138-9. doi: 10.1159/000327237. Epub 2011 Jun 15. No abstract available.

PMID:
21677460
43.

Liver resection and local ablation of breast cancer liver metastases--a systematic review.

Bergenfeldt M, Jensen BV, Skjoldbye B, Nielsen D.

Eur J Surg Oncol. 2011 Jul;37(7):549-57. doi: 10.1016/j.ejso.2011.04.013. Epub 2011 May 24. Review.

PMID:
21605957
44.

Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.

Larsen FO, Pfeiffer P, Nielsen D, Skougaard K, Qvortrup C, Vistisen K, Fromm AL, Jørgensen TL, Bjerregaard JK, Hoegdall E, Jensen BV.

Acta Oncol. 2011 May;50(4):574-7. doi: 10.3109/0284186X.2010.546369.

PMID:
21529301
45.

Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer.

Frederiksen C, Qvortrup C, Christensen IJ, Glimelius B, Berglund A, Jensen BV, Nielsen SE, Keldsen N, Nielsen HJ, Brünner N, Pfeiffer P.

Ann Oncol. 2011 Feb;22(2):369-75. doi: 10.1093/annonc/mdq354. Epub 2010 Jul 19.

PMID:
20643864
46.

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

Qvortrup C, Jensen BV, Jorgensen TL, Nielsen D, Bjerregaard JK, Pfeiffer P.

Acta Oncol. 2010 Aug;49(6):833-6. doi: 10.3109/0284186X.2010.482104.

PMID:
20615171
47.

[Oncological treatment of patients with pancreatic cancer].

Ladekarl M, Jensen BV, Pfeiffer P.

Ugeskr Laeger. 2010 May 3;172(18):1373-6. Danish.

PMID:
20444408
48.

Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.

Dohn LH, Jensen BV, Larsen FO.

Acta Oncol. 2010 Apr;49(3):395-6. doi: 10.3109/02841860903428184. No abstract available.

PMID:
20001495
49.

Systolic versus diastolic cardiac function variables during epirubicin treatment for breast cancer.

Appel JM, Jensen BV, Nielsen DL, Ryberg M, Zerahn B.

Int J Cardiovasc Imaging. 2010 Feb;26(2):217-23. doi: 10.1007/s10554-009-9518-2. Epub 2009 Oct 13.

PMID:
19823942
50.

Plasma YKL-40: a potential new cancer biomarker?

Johansen JS, Schultz NA, Jensen BV.

Future Oncol. 2009 Sep;5(7):1065-82. doi: 10.2217/fon.09.66. Review.

PMID:
19792974

Supplemental Content

Loading ...
Support Center